Ipamorelin + DSIP Blend
How this combination works
The community rationale pairs ipamorelin's GH-stimulating action with DSIP's direct sleep-promoting effects, hypothesising that a GH pulse during early sleep enhances slow-wave sleep architecture while DSIP supports sleep onset and continuity. Ipamorelin is a selective GHS-R1a agonist that triggers a single GH pulse without significant ACTH or cortisol elevation; its approved file lists pre-sleep dosing for sleep quality improvement as a commonly reported community use. DSIP was originally characterised as a sleep-promoting factor; human observational studies — all using intravenous administration — report improved sleep duration, quality, and structure in chronic insomniacs and healthy volunteers. The two compounds act on entirely distinct receptor systems: ipamorelin on GHS-R1a, DSIP on GABAergic, opioidergic, and noradrenergic pathways. This rationale is mechanistic inference; no study has evaluated the combination. Two observations from the component files introduce uncertainty: (1) ipamorelin produced GH-independent increases in food intake and adiposity in mice, an off-target effect unrelated to sleep; and (2) DSIP exhibits a bell-shaped dose-response in animal studies and is rapidly degraded in blood by aminopeptidase cleavage of its N-terminal tryptophan, raising questions about subcutaneous efficacy at community doses relative to the intravenous routes used in all published human studies.
Combined mechanism
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a selective synthetic pentapeptide agonist at the ghrelin receptor (GHS-R1a) that stimulates GH release from the anterior pituitary with potency and efficacy comparable to GHRP-6 (in vitro EC50 = 1.3 nmol/L), but without significant ACTH or cortisol elevation even at doses more than 200-fold above its GH ED50 in swine. In healthy male volunteers it displays dose-proportional pharmacokinetics with a terminal half-life of approximately 2 hours and induces a single episode of GH release peaking at approximately 0.67 hours post-infusion. It also stimulates insulin secretion from pancreatic tissue in vitro via calcium channel and adrenergic receptor pathways and increases food intake and adiposity through GH-independent mechanisms in mice. DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nonapeptide originally isolated from rabbit cerebral venous blood and initially characterised as a sleep-promoting factor, though its definitive link to sleep and its biosynthetic origin remain unconfirmed. DSIP influences oxidative phosphorylation in rat brain mitochondria, modulates GABAergic Cl- flux, stimulates calcium-dependent Met-enkephalin release from rat brainstem slices, mediates antinociception via descending spinal noradrenergic systems, and has described stress-protective activity. It is transported across the blood-brain barrier via a saturable high-affinity mechanism and is rapidly degraded in blood by aminopeptidase cleavage of its N-terminal tryptophan. Plasma DSIP-like immunoreactivity decreases at sleep initiation. A bell-shaped dose-response relationship has been observed across multiple animal experimental settings. In human intravenous studies, a slight arousing effect was observed in the first hour post-injection; sleep-promoting effects emerged from the second hour onward. The two compounds act on distinct receptor systems. If both are administered pre-sleep, ipamorelin's GH peak (~0.67 hours post-injection; PMID 10496658) would coincide with DSIP's initial arousing phase (first hour post-injection; PMID 7028502), before DSIP's sleep-promoting effects emerge. Whether this temporal overlap interacts constructively or disruptively on sleep architecture is completely unstudied. DSIP's human evidence base rests entirely on intravenous administration; its subcutaneous pharmacokinetics and bioavailability in humans are not established in the reviewed literature. No human pharmacokinetic or pharmacodynamic data exist for the combination.
What each component does
Evidence base for this combination
Safety considerations for this combination
- No combination-specific safety data exist for Ipamorelin + DSIP. The signals below come from each compound studied on its own. Component approved files
- GH-independent increase in body fat, increased food intake, and elevated serum leptin observed in mice treated with ipamorelin (s.c., twice daily), including in GH-intact animals. Inherited from Ipamorelin (PMID: 11162489)
- Ipamorelin stimulates insulin secretion from pancreatic tissue of normal and streptozotocin-diabetic rats in vitro via calcium channel and adrenergic receptor pathways, suggesting potential for glycaemic effects. Combined glycaemic effects with DSIP have not been studied. Inherited from Ipamorelin (PMID: 15665799)
- Class-wide adverse effects reported for GHS/ipamorelin in self-administration literature include endocrine and metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions. Inherited from Ipamorelin (PMID: 42395176)
- In streptozotocin-diabetic mice, ipamorelin IV injection produced substantially higher GH levels (150 +/- 35 ug/L) compared to non-diabetic mice (62 +/- 11 ug/L), suggesting unpredictable GH axis responses in diabetic subjects. Inherited from Ipamorelin (PMID: 14630569)
- Headaches were reported by a few patients during intravenous DSIP treatment in a 107-patient clinical study involving alcohol and opiate withdrawal. Inherited from DSIP (PMID: 6548969)
- In human intravenous DSIP studies a slight arousing or activating effect was observed in the first hour post-injection before sleep-promoting effects emerged in the second hour. If this pattern persists after subcutaneous administration it could interact with ipamorelin's GH peak timing window. Inherited from DSIP (PMID: 7028502)
- DSIP is rapidly degraded in blood by aminopeptidase cleavage of its N-terminal tryptophan, contributing to variable and potentially inconsistent in vivo effects. Subcutaneous bioavailability in humans is not established in the reviewed literature. Inherited from DSIP (PMID: 3628078, 8474631)
- DSIP and ipamorelin sourced through unregulated gray-market channels carry documented risks of product contamination, manufacturing impurities, and inaccurate dosing. Pre-blended vials introduce additional uncertainty about per-component doses. Inherited from DSIP and Ipamorelin regulatory status
Contraindications
- Both compounds are commonly dosed pre-sleep. Ipamorelin induces a GH peak at approximately 0.67 hours post-injection in humans (PMID: 10496658), while intravenous DSIP produced a slight arousing effect in the first hour post-injection before sleep-promoting effects emerged from the second hour onward (PMID: 7028502). Whether these overlapping temporal dynamics interact constructively or disruptively on sleep architecture when both are administered subcutaneously pre-sleep has not been studied in any model. Ipamorelin: PMID: 10496658; DSIP: PMID: 7028502
- Ipamorelin is listed on the WADA Prohibited List (PMID: 26578461). DSIP's WADA status is not stated in the reviewed literature and requires manual verification. Competitive athletes using ipamorelin face antidoping consequences regardless of the DSIP component. Ipamorelin: PMID: 26578461; DSIP: WADA status not established in reviewed literature (dsip.json regulatory_status.WADA)
- Neither compound is approved by the FDA or any other regulatory authority for any sleep indication. DSIP's US regulatory status is not specified in the reviewed literature. The combination has not been evaluated in any clinical trial; the absence of combination-specific contraindications reflects that absence of study, not established safety. Ipamorelin: PMID: 41966639, 42160466; DSIP: regulatory status not stated in reviewed abstracts (dsip.json)
- DSIP displays a bell-shaped dose-response in multiple animal models (PMID: 2322843, 6548967), meaning doses above or below the effective range may be inactive or produce different effects. Community subcutaneous doses have not been validated against the intravenous doses used in all published human studies. Whether co-administration with ipamorelin shifts DSIP's effective dose window is unknown. DSIP: PMID: 2322843, 6548967
- Plasma DSIP-like immunoreactivity shows a significant correlation with predexamethasone cortisol in healthy controls, suggesting glucocorticoid involvement in DSIP regulation (PMID: 9606527). Ipamorelin does not significantly elevate cortisol at GH-releasing doses (PMID: 9849822); however, the neuroendocrine interaction between GH-axis stimulation by ipamorelin and DSIP's glucocorticoid-related regulatory activity is completely unstudied. DSIP: PMID: 9606527; Ipamorelin: PMID: 9849822